The first venture of lipid-based mRNA cancer therapy was reported by Conry and co-workers in 1995, with the administration of luciferase and mRNA encoding carcinoembryonic antigen as a cancer vaccine [145]. This evidence concerns the gene CEACAM5 and cancer.